Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...

GSK has walked away from a $2.2 billion biobucks neurodegenerative disease pact with Alector that has seen both drugs ...

The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech ...

AstraZeneca is paying Sino Biopharmaceutical $200 million upfront for ex-China rights to a late-phase challenger to Merck & ...

Satellos Bioscience has shared evidence that its Duchenne muscular dystrophy (DMD) drug candidate is active in adults, ...

Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...

The merged entity will retain the Scipher brand and take advantage of Chemomab’s Nasdaq listing, although the ticker will ...

As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal ...

Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ (PVT) viral vector platform for developing ...

Caidya and Simbec-Orion have united to create a new platform aimed at helping drug development programs accelerate and scale.

As U.S. lawmakers continue to scrutinize the consequences of China’s expanding role in biotech innovation, industry insiders ...

MeiraGTx has secured an investment of up to $400 million from Oberland Capital to help get its late-stage gene therapies | As ...